You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Time-perspective in cardiovascular risk of NSAID use after first-time myocardial infarction

Olsen, Anne-Marie Schjerninga; Gislason, Gunnar H.a,b,c; Fosbøl, Emil L.a,e,d

Current Opinion in Cardiology:
doi: 10.1097/HCO.0b013e3283652dad
ISCHEMIC HEART DISEASE: Edited by Peter H. Stone
Abstract

Purpose of review: Despite the fact that NSAIDs are not recommended among patients with established cardiovascular disease, many patients receive NSAID treatment for a short period of time. However, up until recently, data on the relationship between treatment duration and associated cardiovascular risk were sparse and have not been summarized.

Recent findings: A series of recent studies of patients with prior myocardial infarction (MI) demonstrated that short-term treatment with most NSAIDs is associated with an increased cardiovascular risk relative to no NSAID treatment. These studies furthermore demonstrated that NSAID use among patients with first-time MI was associated with persistently increased risk of all-cause mortality and of a composite of coronary death or nonfatal recurrent MI for at least 5 years thereafter.

Summary: The present review indicates that there is no apparent well-tolerated therapeutic window for associated cardiovascular risk and NSAID use in patients with prior MI. Further randomized studies are warranted to evaluate the cardiovascular safety of NSAIDs, but, at this point, the overall evidence suggests advising caution in using NSAIDs at all times after MI. Legislation bodies need to address this issue of public health proportions, as studies have shown that utilization rates of NSAID keep increasing.

Author Information

aDepartment of Cardiology, Copenhagen University Hospital Gentofte, Hellerup

bFaculty of health and medical sciences, University of Copenhagen

cNational Institute of Public Health, University of Southern Denmark

dDepartment of Cardiology, the Heart Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

eDuke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA

Correspondence to Anne-Marie Schjerning Olsen, MD, Department of Cardiology – Post 635, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65, 2900 Hellerup, Denmark. Tel: +45 60 16 93 40; fax: +45 70201283; e-mail: amschjerning@gmail.com

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins